Xiamen Amoytop Biotech (SHA:688278) subsidiary, Bosai Gene Transcription Technology, will acquire some assets of Skyline Therapeutics for $15 million, with additional milestones and sales-based payments of up to $43 million, according to a Monday filing with the Shanghai bourse.
The deal, approved by the company's board, will make Skyline a wholly owned subsidiary.
The acquisition awaits regulatory and shareholder approvals.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.